All In Biotech

NDA 050575 · US Antibiotics

Augmentin '125'

Amoxicillin, Clavulanate Potassium · Oral

Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

Aug 6, 1984

Approved uses

1

Original approval plus efficacy supplements

Registered trials

918

176 Phase 3, 89 recruiting

FAERS reports

27,162

21,127 serious, 2,624 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 26, 2026.

AUGMENTIN is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by beta‑lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species. Urinary Tract Infections - caused by beta‑lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species. AUGMENTIN is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta‑lactamase inhibitor indicated for treatment of the following infections in adults and pediatric patients: ( 1 ) Lower respiratory tract infections Acute bacterial otitis media Sinusitis Skin and skin structure infections Urinary tract infections Limitations of Use When susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, AUGMENTIN should not be used. ( 1 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of AUGMENTIN and other antibacterial drugs, AUGMENTIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1 ) Limitations of Use When susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, AUGMENTIN should not be used. Usage To reduce the development of drug‑resistant...

Mechanism: AUGMENTIN is an antibacterial drug [see Microbiology ( 12.4 )] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 6, 1984 Original approval · Type 3 - New Dosage Form
2 products under this application
  • AUGMENTIN '125' · AMOXICILLIN 125MG/5ML; CLAVULANATE POTASSIUM EQ 31.25MG BASE/5ML · FOR SUSPENSION, ORAL · Prescription · TE AB
  • AUGMENTIN '250' · AMOXICILLIN 250MG/5ML; CLAVULANATE POTASSIUM EQ 62.5MG BASE/5ML · FOR SUSPENSION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Amoxicillin" as an intervention, any sponsor and status, largest first.

All 918 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea1,873
  • drug hypersensitivity1,824
  • nausea1,449
  • dyspnoea1,421
  • pyrexia1,395
  • fatigue1,292
  • pneumonia1,204
  • vomiting1,173
  • rash1,031
  • pain991
  • headache947
  • acute kidney injury860

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004563
2005450
2006205
2007142
2008140
2009716
2010673
2011869
2012927
20131,030
20141,246
20151,602
20162,143
20171,954
20182,378
20192,414
20202,029
20211,337
20221,405
20231,423
20241,386
20251,228
2026898

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,171 on PubMed

Sponsor: US Antibiotics · Also marketed as Augmentin '250'

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.